JPWO2020180591A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020180591A5 JPWO2020180591A5 JP2021550277A JP2021550277A JPWO2020180591A5 JP WO2020180591 A5 JPWO2020180591 A5 JP WO2020180591A5 JP 2021550277 A JP2021550277 A JP 2021550277A JP 2021550277 A JP2021550277 A JP 2021550277A JP WO2020180591 A5 JPWO2020180591 A5 JP WO2020180591A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chimeric antigen
- antigen receptor
- domain
- dll3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024208345A JP2025041642A (ja) | 2019-03-01 | 2024-11-29 | Ｄｌｌ３標的化キメラ抗原受容体および結合剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962812585P | 2019-03-01 | 2019-03-01 | |
| US62/812,585 | 2019-03-01 | ||
| US202062969976P | 2020-02-04 | 2020-02-04 | |
| US62/969,976 | 2020-02-04 | ||
| PCT/US2020/020042 WO2020180591A1 (en) | 2019-03-01 | 2020-02-27 | Dll3 targeting chimeric antigen receptors and binding agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024208345A Division JP2025041642A (ja) | 2019-03-01 | 2024-11-29 | Ｄｌｌ３標的化キメラ抗原受容体および結合剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022523781A JP2022523781A (ja) | 2022-04-26 |
| JPWO2020180591A5 true JPWO2020180591A5 (enExample) | 2023-03-06 |
| JP7702874B2 JP7702874B2 (ja) | 2025-07-04 |
Family
ID=70057267
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021550277A Active JP7702874B2 (ja) | 2019-03-01 | 2020-02-27 | Ｄｌｌ３標的化キメラ抗原受容体および結合剤 |
| JP2024208345A Pending JP2025041642A (ja) | 2019-03-01 | 2024-11-29 | Ｄｌｌ３標的化キメラ抗原受容体および結合剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024208345A Pending JP2025041642A (ja) | 2019-03-01 | 2024-11-29 | Ｄｌｌ３標的化キメラ抗原受容体および結合剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11673953B2 (enExample) |
| EP (1) | EP3930744A1 (enExample) |
| JP (2) | JP7702874B2 (enExample) |
| KR (1) | KR20210138574A (enExample) |
| CN (1) | CN113543799B (enExample) |
| AU (1) | AU2020231308B2 (enExample) |
| BR (1) | BR112021016984A2 (enExample) |
| CA (1) | CA3131908A1 (enExample) |
| CO (1) | CO2021011326A2 (enExample) |
| IL (1) | IL285943A (enExample) |
| MX (1) | MX2021010441A (enExample) |
| PE (1) | PE20220495A1 (enExample) |
| PH (1) | PH12021551720A1 (enExample) |
| SG (1) | SG11202108011UA (enExample) |
| TW (1) | TW202045547A (enExample) |
| WO (1) | WO2020180591A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| CN112955465A (zh) | 2018-07-03 | 2021-06-11 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| CN119661722A (zh) | 2019-02-21 | 2025-03-21 | 马伦戈治疗公司 | 结合t细胞相关癌细胞的多功能分子及其用途 |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| GB2609554B (en) | 2020-01-03 | 2025-08-20 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| WO2022020456A2 (en) | 2020-07-21 | 2022-01-27 | Allogene Therapeutics, Inc. | Chimeric antigen receptors with enhanced signaling and activities and uses thereof |
| AU2021356681A1 (en) * | 2020-10-09 | 2023-05-18 | Eureka Therapeutics Inc. | Compositions targeting ndc80/mhc complexes and uses thereof |
| CA3201115A1 (en) | 2020-12-21 | 2022-06-30 | Shanshan LANG | Protease-activating cd45-gate car |
| MX2023008809A (es) | 2021-01-29 | 2023-08-04 | Allogene Therapeutics Inc | ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS. |
| US20240239878A1 (en) * | 2021-05-08 | 2024-07-18 | Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. | Binding molecule against dll3 and use thereof |
| AU2022339815A1 (en) * | 2021-09-02 | 2024-03-14 | Memorial Hospital For Cancer And Allied Diseases | Antigen recognizing receptors targeting dll3 and uses thereof |
| WO2023034557A1 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Radioligand binding to anti-dll3 antibodies for pretargeted pet imaging and therapeutic uses thereof |
| CN114181311B (zh) * | 2021-12-20 | 2023-06-20 | 华东师范大学 | 一种全人源抗DLL3 scFv及其在CART细胞治疗中的应用 |
| CA3244596A1 (en) | 2022-03-29 | 2023-10-05 | Allogene Therapeutics, Inc. | Chimeric switch receivers for converting immunoactive signals into stimulation signals |
| CN119654406A (zh) | 2022-07-29 | 2025-03-18 | 艾洛基治疗公司 | 具有降低的基因表达以减轻免疫细胞识别的经工程化的细胞 |
| CN116003628A (zh) * | 2022-08-15 | 2023-04-25 | 南京博安生物技术有限公司 | 靶向人dll3抗原的全人源特异性嵌合抗原受体及其应用 |
| AU2023329484A1 (en) * | 2022-08-26 | 2025-02-20 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3) |
| CN116813784B (zh) * | 2023-05-17 | 2024-03-01 | 星奕昂(上海)生物科技有限公司 | 靶向dll3的抗体及其应用 |
| CN118878682B (zh) * | 2023-07-11 | 2025-11-04 | 四川大学 | 靶向人dll3的嵌合抗原受体t细胞及其应用 |
| CN117126296B (zh) * | 2023-07-20 | 2024-02-23 | 广州默锐医药科技有限公司 | 一种car-t细胞及其构建方法和应用 |
| WO2025082340A1 (zh) * | 2023-10-16 | 2025-04-24 | 上海先博生物科技有限公司 | 一种靶向δ样配体3的CAR及应用 |
| WO2025096560A1 (en) | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Engineered cells |
| WO2025184421A1 (en) * | 2024-02-28 | 2025-09-04 | Juno Therapeutics, Inc. | Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods |
| WO2025212519A1 (en) * | 2024-04-01 | 2025-10-09 | Moonlight Bio, Inc. | Dll3 binding proteins and uses thereof |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
| US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| ES2162863T3 (es) | 1993-04-29 | 2002-01-16 | Unilever Nv | Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae. |
| US20030036654A1 (en) | 1994-08-18 | 2003-02-20 | Holt Dennis A. | Synthetic multimerizing agents |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| HK1047770A1 (zh) | 2000-02-24 | 2003-03-07 | Xcyte Therapies, Inc. | 细胞的同时刺激与浓缩 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| KR100857943B1 (ko) | 2000-11-30 | 2008-09-09 | 메다렉스, 인코포레이티드 | 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류 |
| JP2005538706A (ja) | 2001-07-12 | 2005-12-22 | ジェファーソン フーテ， | スーパーヒト化抗体 |
| WO2005097832A2 (en) | 2004-03-31 | 2005-10-20 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
| WO2011146862A1 (en) | 2010-05-21 | 2011-11-24 | Bellicum Pharmaceuticals, Inc. | Methods for inducing selective apoptosis |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012103279A2 (en) | 2011-01-26 | 2012-08-02 | Ariad Pharmaceuticals, Incorporated | Methods and compositions for the synthesis of multimerizing agents |
| NZ743310A (en) | 2011-03-23 | 2022-11-25 | Fred Hutchinson Cancer Center | Method and compositions for cellular immunotherapy |
| SMT201700467T1 (it) | 2012-02-24 | 2017-11-15 | Abbvie Stemcentrx Llc | Modulatori di dll3 e metodi di uso |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| KR102064230B1 (ko) | 2013-02-15 | 2020-01-13 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 키메라 항원 수용체 및 이의 이용 방법 |
| KR20150131218A (ko) | 2013-03-14 | 2015-11-24 | 벨리쿰 파마슈티컬스, 인크. | T 세포 증식의 제어 방법 |
| CA2956667A1 (en) | 2013-07-29 | 2015-02-05 | Bluebird Bio, Inc. | Multipartite signaling proteins and uses thereof |
| JP6793902B2 (ja) | 2013-12-20 | 2020-12-02 | ノバルティス アーゲー | 調節可能キメラ抗原受容体 |
| EP4215603A1 (en) | 2014-02-04 | 2023-07-26 | Kite Pharma, Inc. | Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof |
| CN106132423B (zh) | 2014-02-14 | 2020-07-31 | 贝里坤制药股份有限公司 | 用诱导型嵌合多肽活化t细胞的方法 |
| EP3107576A4 (en) | 2014-02-21 | 2017-09-06 | Abbvie Stemcentrx LLC | Anti-dll3 antibodies and drug conjugates for use in melanoma |
| KR102329836B1 (ko) | 2015-01-26 | 2021-11-19 | 셀렉티스 | 암 면역치료를 위한 항-CLL1 특이적 단일-체인 키메라 항원 수용체들(scCARS) |
| MA41613A (fr) | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
| TW202346349A (zh) | 2015-07-31 | 2023-12-01 | 德商安美基研究（慕尼黑）公司 | Dll3及cd3抗體構築體 |
| WO2017058944A1 (en) * | 2015-09-29 | 2017-04-06 | Amgen Inc. | Asgr inhibitors |
| PT3436030T (pt) | 2016-04-01 | 2022-11-18 | Amgen Inc | Recetores quiméricos e métodos para a sua utilização |
| WO2018073394A1 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Cell death inducing chimeric antigen receptors |
| WO2018151841A1 (en) * | 2017-02-17 | 2018-08-23 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
-
2020
- 2020-02-27 WO PCT/US2020/020042 patent/WO2020180591A1/en not_active Ceased
- 2020-02-27 SG SG11202108011UA patent/SG11202108011UA/en unknown
- 2020-02-27 BR BR112021016984A patent/BR112021016984A2/pt unknown
- 2020-02-27 CA CA3131908A patent/CA3131908A1/en active Pending
- 2020-02-27 JP JP2021550277A patent/JP7702874B2/ja active Active
- 2020-02-27 US US16/802,822 patent/US11673953B2/en active Active
- 2020-02-27 CN CN202080018238.0A patent/CN113543799B/zh active Active
- 2020-02-27 PH PH1/2021/551720A patent/PH12021551720A1/en unknown
- 2020-02-27 KR KR1020217025642A patent/KR20210138574A/ko active Pending
- 2020-02-27 AU AU2020231308A patent/AU2020231308B2/en active Active
- 2020-02-27 TW TW109106500A patent/TW202045547A/zh unknown
- 2020-02-27 MX MX2021010441A patent/MX2021010441A/es unknown
- 2020-02-27 EP EP20715560.7A patent/EP3930744A1/en active Pending
- 2020-02-27 PE PE2021001410A patent/PE20220495A1/es unknown
-
2021
- 2021-08-27 CO CONC2021/0011326A patent/CO2021011326A2/es unknown
- 2021-08-29 IL IL285943A patent/IL285943A/en unknown
-
2023
- 2023-04-27 US US18/308,143 patent/US20230287120A1/en active Pending
-
2024
- 2024-11-29 JP JP2024208345A patent/JP2025041642A/ja active Pending